drugset
drugset / Trial / NCT07010523

Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

NCT07010523 ↗

Recruiting 24 enrolled Zhejiang University UTC Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety, tolerability and preliminary efficacy of Anti-Mesothelin CAR-T cell injection in patients with Mesothelin-positive advanced malignant solid tumors.

Timeline

Start
2024-10-15
Primary completion
2026-10-14
Completion
2027-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Anti-mesothelin CAR-T cells Cell therapy 100000 cells/kg Intravenous
Subject Anti-mesothelin CAR-T cells Cell therapy 1e+06 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Background Fludarabine Small molecule 25 mg/m2 Intravenous

Indications

neoplasm